Afoxepim® vial (Cefepime)

Afoxapim® Cefepime

500 mg, 1 g and 2 g injection vial

This medicine has been prescribed for your current condition. Therefore, do not use it in similar cases or recommend it to others.

General instructions:

Before using this medicine, consult your doctor in the following cases:

If you have a history of allergy to penicillins, cephalosporins, penicillin-like drugs, penicillamine, preservatives and dyes.

If you have other diseases, including: digestive diseases, bleeding disorders, liver and kidney failure.

If you are taking any other medication.

Before performing laboratory tests (especially urine sugar)

If you are pregnant and breastfeeding

Use during pregnancy and breastfeeding:

Pregnancy: This medicine is in the FDA category B. Use of this medicine during pregnancy should be under the advice of a doctor.

Breastfeeding: Cefepime is excreted in small amounts in breast milk, so the benefits of the drug should be weighed against its risks.

Warnings:

In case of any allergic reaction to the drug, stop taking the drug. In severe cases, immediate medical attention is required.

Take the drug at regular intervals and complete the course of treatment.

If the symptoms of the disease do not improve, inform your doctor.

In case of diarrhea, contact your doctor and avoid taking antidiarrheal drugs on your own.

This drug may cause errors in the results of a sugar test (via urine test), so inform your doctor before changing the dose of the antidiabetic drug.

In patients with renal failure, the dose should be adjusted according to the severity of the disease.

Intravenous infusion should be performed over a period of 30 minutes.

Dosage:

The doctor determines the amount of the drug. However, the usual dosage of the drug is as follows:

Adults:

In the treatment of complicated intra-abdominal infections: 2 grams intravenously every 12 hours with metronidazole for 7-10 days

In the treatment of septicemia, moderate to severe skin and soft tissue infections, severe urinary tract infections: 2 grams intravenously every 12 hours for 10 days

In the treatment of febrile neutropenia: 2 grams intravenously every 8 hours for 7 days or until neutropenia resolves.

Note: In the treatment of febrile neutropenia, in patients whose fever has resolved but neutropenia persists for more than 7 days, the need for continued antibiotic therapy should be re-evaluated.

In the treatment of moderate to severe pneumonia: 1-2 grams intravenously every 12 hours for 10 days

In the treatment of mild to moderate urinary tract infections: 500 mg to 1 gram intravenously or intramuscularly every 12 hours for 7 to 10 days

Children:

For the treatment of moderate to severe pneumonia, moderate to severe skin and soft tissue infections, mild to moderate urinary tract infections: In infants and children 2 months to 16 years of age (weighing less than 40 kg), 50 mg per kg of body weight intravenously every 12 hours for 10 days (for urinary tract infections, 7 to 10 days).

For the treatment of severe urinary tract infections: In infants and children 2 months to 16 years of age (weighing less than 40 kg), 50 mg per kg of body weight intramuscularly or intravenously every 12 hours for 7 to 10 days.

Note: Intramuscular injection of cefepime is only used for mild to moderate urinary tract infections caused by E. coli, where intramuscular injection is a more appropriate route of administration.

In the treatment of febrile neutropenia: In infants and children 2 months to 16 years of age (weighing less than 40 kg), 50 mg per kg of body weight intravenously every 8 hours for 7 days or until neutropenia resolves.

The maximum dose in children should not exceed the recommended dose in adults.

How to use the drug:

For intramuscular injection, add 1.3 and 2.4 ml of sterile water for injection, 0.9% sodium chloride solution for injection, or 5% dextrose solution for injection, respectively, to 500 mg or 1 g cefepime vials and shake well.

For intravenous infusion, add 5 and 10 ml of 0.9% sodium chloride solution for injection or 5% dextrose solution for injection, respectively, to 500 mg cefepime vials and 1 or 2 g vials and shake well. Dilute the resulting solution again with 50-100 ml of the same initial injection solution and inject slowly over 30 minutes.

Solutions ready for injection are colorless to amber, do not use if the solution changes color and darkens.

After dissolving the powder, do not inject if foreign particles or turbidity of the solution are observed.

Drug interactions:

Avoid mixing cefepime with ampicillin solutions with a concentration greater than 40 mg/ml, aminophylline, gentamicin, metronidazole, netilmycin, tobramycin or vancomycin. If simultaneous administration with cefepime is required, these drugs should be injected at two separate sites.

Side effects:

Every drug may cause some unwanted side effects in parallel with the desired therapeutic effect. Since not all of these side effects occur in the same person, consult your doctor if any of the following side effects occur:

Blood disorders such as eosinophilia, neutropenia, thrombocytopenia, leukopenia, hemolytic anemia, and agranulocytosis, allergic reactions such as fever, itching, and rash, thrombophlebitis after intravenous injection, pain at the injection site after intramuscular injection, nephrotoxicity (in high doses in elderly patients with a history of renal failure or in cases of concomitant use with nephrotoxic drugs such as aminoglycosides), increased liver enzyme activity, seizures and signs of brain toxicity (especially in high doses), gastrointestinal complications such as nausea, diarrhea, vomiting, and pseudomembranous colitis.

Storage conditions:

Store the dry product at a temperature below 25°C, away from light, and in the box until use.

Avoid using expired medication.

Keep the medication out of the reach of children.

Pharmaceutical forms and packaging:

Cefepime 500 mg injection vial: Each vial contains 500 mg of cefepime (as hydrochloride monohydrate) and is packaged in a box of 20 with a leaflet.

Cefepime 1 g injection vial: Each vial contains 1 g of cefepime (as hydrochloride monohydrate) and is packaged in a box of 20 with a leaflet.

Cefepime 2 g injection vial: Each vial contains 2 g of cefepime (as hydrochloride monohydrate) and is packaged in a box of 20 with a leaflet.